Invokana (in-vo-KAHN-uh, canagliflozin), the first in a new class of oral drugs for type 2 diabetes
May 2013
Reps will promote Invokana (in-vo-KAHN-uh, canagliflozin), the first in a new class of oral drugs for type 2 diabetes.
You'll hear it referred to as an "SGLT2 inhibitor"...because it inhibits sodium-glucose co-transporter 2 in the kidneys. This allows more glucose to spill into the urine instead of being reabsorbed.
Reps will point out that Invokana reduces A1C by 1% when used alone...and it has a low risk of hypoglycemia.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote